Skip to main content

Table 3 Cross-sectional studies in populations including sporadic Alzheimer's disease patients

From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

     

Values in AD patients

 

Study

Subjects

Mean age (years)

Platform and antibodies

CV

Aβ1-40

Aβ1-42

Aβ1-42/Aβ1-40

Other

Mehta et al. 2000 [55]

61 CN

78 AD

67

74

ELISA 6E10

R162

R164

<18%

↑

=

-

 

Mayeux et al. 2003 [27]

79 AD

365 CN

83.2 75.5

ELISA 6E10

R182

R165

-

=

↑

NA

 

Fukumoto et al. 2003 [26]

92 CN

96 PD

37 MCI

146 AD

69

66.0 72.6

76

ELISA Takeda

<10%

=

=

=

 

Assini et al. 2004 [41]

72 CN

88 MCI

73

75

ELISA IBL

-

-

-

-

Increased Aβ1-42 in MCI women

Lewczuk et al. 2010 [56]

137 MCIp

62 MCI-OD 127 AD

25 OD

67.4 63.3 70.8 66.6

xMAP INNO-BIA

<10%

-

-

-

MCI and AD with AD-like CSF ↓ Aβ1-42 & ↓ Aβ1-42/Aβ1-40

Lui et al. 2010 [14]

724 CN

122 MCI

186 AD

70.0 75.9 78.6

ELISA Mehta xMAP INNO-BIA

-

=

↓

=

 

Le Bastard et al. 2010 [12]

47 CN

50 non-AD

47 AD

69

74

82

xMAP INNO-BIA

<10%

=

=

=

↓ Aβ1-42/AβN-42

Toledo et al. 2011 [10], Figurski et al. 2012 [48]

187 CNs

10 CNp

162 MCIs

145 MCIp

162 AD

75.8 78.4 74.7 74.6 75.3

xMAP INNO-BIA

<10%

=

=

=

Interaction between age and diagnosis defined by CSF

  1. AD, Alzheimer's disease; CN, cognitively normal; CNp, cognitively normal progression; CNs, cognitive normal stable; CV, coefficient of variation; MCI, mild cognitive impairment; MCI-OD, mild cognitive impairment, progression to non-AD dementia; MCIp, mild cognitive impairment progressor (to AD); MCIs, mild cognitive impairment stable; NA, not available; OD, other dementia; PD, Parkinson's disease.